Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    AGN

SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets 

Allergan, Inc. : Allergan : Studies Show Botox Treats Overactive Bladder

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/28/2012 | 03:54pm CET

Allergan Inc. (AGN) filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladder as two Phase III clinical trials showed the injectible neurotoxin significantly reduced urinary incontinence when compared with a placebo.

Botox is approved for both cosmetic use, such as fighting wrinkles, and for various medical issues, including urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan on Wednesday said Botox met the primary endpoints of significantly reducing urinary incontinence, or bladder leakage, episodes in patients who have an inadequate response to or are intolerant of an anticholinergic medication.

Based on the results, Allergan has submitted a supplemental biologics license application with the U.S. Food and Drug Administration and an application with European Regulatory authorities to approve the use of Botox by adult patients not managed by an anticholinergic treatment.

The drug maker has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (MAPP) to jointly promote Map's experimental migraine treatment Levadex.

Allergan reported last month its fourth-quarter earnings rose 6.3% as higher specialty pharmaceuticals sales contributed to a 7.1% revenue jump.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN, INC.
01/18 ALLERGAN : To pay $15m penalty over merger
01/17 Allergan to pay $15 million over failing to disclose merger talks
01/17 ALLERGAN : and Gedeon Richter Announce Positive Phase III Results for Ulipristal..
01/16 ALLERGAN : Big pharma establishes new industry standards group
01/10 ALLERGAN : Enters Licensing Agreement with Assembly Biosciences to Obtain Worldw..
01/10 ASSEMBLY BIOSCIENCES (NASDAQ : ASMB) Files An 8-K Entry into a Material Definiti..
01/09 IRONWOOD PHARMACEUTICALS,INC. (NASDA : IRWD) Files An 8-K Results of Operations ..
01/09 ALLERGAN : continues to acquire companies with 2 more deals
01/08 ALLERGAN PLC (NYSE : AGN) Files An 8-K Departure of Directors or Certain Officer..
01/07 ALLERGAN : 11 Surprising Uses For Botox
More news
Sector news : Pharmaceuticals - NEC
08:57a ASTRAZENECA : GSK grabs Astra executive to replace exiting pharma head
08:48aDJBusiness Watch -- WSJ
08:28aDJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave
01/18DJCSL : Expects Higher Profits On Strong Immunoglobulin Sales -- Update
01/18DJCSL : Expects Higher 1st Half Profits On Strong Immunoglobulin Sales
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 MANNKIND : A Head Pain Gain Or A Pocket-Book Drain?
2015 Tracking Dan Loeb's Third Point Portfolio - Q1 2015 Update
2015 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2015 Update
2015 Time Warner Is A Buy - Cramer's Lightning Round (5/21/15)
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
Ambrose Robert Douglas Bailey Chairman & President
Scott M. Whitcup Chief Scientific Officer & Executive VP-Research
Raymond H. Diradoorian Executive VP-Global Technical Operations
Maria Teresa Hilado Director
Joann Bradley Investor Relations Contact
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN, INC.13.00%0
JOHNSON & JOHNSON-0.44%312 045
ROCHE HOLDING LTD.1.29%203 230
PFIZER INC.-1.39%194 369
NOVARTIS AG-3.71%189 507
MERCK & CO., INC.3.91%168 654
More Results